I-Mab
NASDAQ:IMAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9397
2.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
I-Mab
I-Mab
Selling, General & Administrative
I-Mab
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
I-Mab
NASDAQ:IMAB
|
Selling, General & Administrative
-¥453m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Selling, General & Administrative
-¥10.9B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Selling, General & Administrative
-¥1.1B
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-122%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Selling, General & Administrative
-¥1.9B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Selling, General & Administrative
-¥781.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-17%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Selling, General & Administrative
-¥3.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-28%
|
|
I-Mab
Glance View
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
See Also
What is I-Mab's Selling, General & Administrative?
Selling, General & Administrative
-453m
CNY
Based on the financial report for Dec 31, 2023, I-Mab's Selling, General & Administrative amounts to -453m CNY.
What is I-Mab's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-47%
Over the last year, the Selling, General & Administrative growth was 44%. The average annual Selling, General & Administrative growth rates for I-Mab have been -4% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
